These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 31751573)
1. Unilateral lesion of the nigroestriatal pathway with 6-OHDA induced allodynia and hyperalgesia reverted by pramipexol in rats. Romero-Sánchez HA; Mendieta L; Austrich-Olivares AM; Garza-Mouriño G; Benitez-Diaz Mirón M; Coen A; Godínez-Chaparro B Eur J Pharmacol; 2020 Feb; 869():172814. PubMed ID: 31751573 [TBL] [Abstract][Full Text] [Related]
2. Synergistic antiallodynic and antihyperalgesic interaction between L-DOPA and celecoxib in parkinsonian rats is mediated by NO-cGMP-ATP-sensitive K Aguirre-Vidal Y; Rodríguez-Ramos C; Mendieta L; Romero-Sánchez HA; Garza-Mouriño G; Benítez-Díaz Mirón MI; Castellanos-Páez ME; Pérez-Ramos J; Godínez-Chaparro B Eur J Pharmacol; 2020 Dec; 889():173537. PubMed ID: 32971091 [TBL] [Abstract][Full Text] [Related]
3. Pramipexole inhibits formalin-induce acute and long-lasting mechanical hypersensitivity via NF-kB pathway in rats. Santamaria-Anzures J; Pérez-Ramos J; Mendoza-Pérez F; Godínez-Chaparro B Drug Dev Res; 2023 Apr; 84(2):253-261. PubMed ID: 36651647 [TBL] [Abstract][Full Text] [Related]
4. Pramipexole attenuates 6-OHDA-induced Parkinson's disease by mediating the Nurr1/NF-κB pathway. Gao H; Wang D; Wang YL; Mao JP; Jiang S; Yang XL Mol Biol Rep; 2021 Apr; 48(4):3079-3087. PubMed ID: 33891271 [TBL] [Abstract][Full Text] [Related]
5. Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats. Jiménez-Urbieta H; Gago B; Quiroga-Varela A; Rodríguez-Chinchilla T; Merino-Galán L; Delgado-Alvarado M; Navalpotro-Gómez I; Belloso-Iguerategui A; Marin C; Rodríguez-Oroz MC Psychopharmacology (Berl); 2020 Aug; 237(8):2419-2431. PubMed ID: 32440779 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Fragment C Domain of Tetanus Toxin and Pramipexole in an Animal Model of Parkinson's Disease. Patricio F; Parra I; Martínez I; Pérez-Severiano F; Montes S; Aguilera J; Limón ID; Tizabi Y; Mendieta L Neurotox Res; 2019 Apr; 35(3):699-710. PubMed ID: 30607904 [TBL] [Abstract][Full Text] [Related]
8. Lesion of the subthalamic nucleus reverses motor deficits but not death of nigrostriatal dopaminergic neurons in a rat 6-hydroxydopamine-lesion model of Parkinson's disease. Rizelio V; Szawka RE; Xavier LL; Achaval M; Rigon P; Saur L; Matheussi F; Delattre AM; Anselmo-Franci JA; Meneses M; Ferraz AC Braz J Med Biol Res; 2010 Jan; 43(1):85-95. PubMed ID: 19967265 [TBL] [Abstract][Full Text] [Related]
9. Reinforcing properties of Pramipexole in normal and parkinsonian rats. Engeln M; Ahmed SH; Vouillac C; Tison F; Bezard E; Fernagut PO Neurobiol Dis; 2013 Jan; 49():79-86. PubMed ID: 22940424 [TBL] [Abstract][Full Text] [Related]
10. Pirouetting pigs: A large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway. Christensen AB; Sørensen JCH; Ettrup KS; Orlowski D; Bjarkam CR Brain Res Bull; 2018 May; 139():167-173. PubMed ID: 29462643 [TBL] [Abstract][Full Text] [Related]
11. Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra. Konieczny J; Czarnecka A; Lenda T; Kamińska K; Lorenc-Koci E Behav Brain Res; 2014 Mar; 261():79-88. PubMed ID: 24361083 [TBL] [Abstract][Full Text] [Related]
12. Adaptive down-regulation of the serotonin transporter in the 6-hydroxydopamine-induced rat model of preclinical stages of Parkinson's disease and after chronic pramipexole treatment. Berghauzen-Maciejewska K; Wardas J; Kosmowska B; Domin H; Śmiałowska M; Głowacka U; Ossowska K Neuroscience; 2016 Feb; 314():22-34. PubMed ID: 26628402 [TBL] [Abstract][Full Text] [Related]